Benzinga's Weekend M&A Chatter
The following are the M&A deals, rumors and chatter circulating on Wall Street for Friday December 11 through Sunday December 13, 2015:
Dow Chemical, Dupont Announce Merger of Equals
DuPont (NYSE: DD) and Dow Chemical (NYSE: DOW) announced Friday, that their boards of directors unanimously approved a definitive agreement for the companies to combine in an all-stock merger of equals. The combined company DowDuPont, will be separated into three independent, publicly traded companies: a pure-play Agriculture company; a pure-play Material Science company and a Specialty Products company.
Dow shareholders will receive 1.00 share of DowDuPont for each Dow share. DuPont shareholders will receive 1.282 shares in DowDuPont for each DuPont share.
The merger is expected to close in H2 of 2016
DuPont fell 5.51% Friday, closing at $70.44. Dow Chemical shares fell 2.8%, to close at $53.37.
Tsinghua Unigroup to Acquire 25% of Chipmos Taiwan for NT$12B
ChipMOS Technologies (NASDAQ: IMOS) announced Friday, that the Board of Directors of its 58.0% owned subsidiary ChipMOS TECHNOLOGIES INC. has agreed to sell 299,252,000 common shares of ChipMOS Taiwan to Tsinghua Unigroup NT$40.0 per share. Tsinghua Unigroup will pay approximately $366 million ofr the 25% stake.
ChipMOS Technologies rose 4.45% Friday, closing at $19.48.
Shire Said to be in Talks to Acquire Baxalta
Shire Plc (NASDAQ: SHPG) is said to be in talks to acquire Baxalta Inc. (NYSE: BXLT), according to sources as reported by Bloomberg on Friday. Sources say the cash and stock offer could come in the next several weeks.
Reuters reported last month, that Shire was preparing to make a new offer for Baxalta, following rejection of a $30 billion bid in August, which valued Baxalta at $45.23 per share.
Baxlata closed at $37.04 on Friday, down 1.7%. Shire fell 2.49%, closing at $191.97.
Astrazeneca Said to be in Talks to Acquire Acerta Pharma
AstraZeneca PLC (NYSE: AZN) is said to be in talks to acquire Acerta Pharma BV and its blood cancer treatment acalabrutinib, according to sources as reported by the Wall Street Journal on Friday. Sources say the purchase price could be more than $5 billion for the Netherlands-based company.
A deal reportedly could be announced by year-end.
Astrazeneca closed at $33.25 on Friday, down 0.66%.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.